Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503171 | 1.00 | TLR2 (0.41) | TLR2TLR1BACE1KMT2AL3MBTL1 | |
| SCHEMBL1913190 | 0.87 | KMT2A (0.43) | TLR2TLR1BACE1KMT2AL3MBTL1 | |
| SCHEMBL1913332 | 0.87 | KMT2A (0.43) | TLR2TLR1BACE1KMT2AL3MBTL1 | |
| SCHEMBL1913192 | 0.87 | KMT2A (0.43) | TLR2TLR1BACE1KMT2AL3MBTL1 | |
| SCHEMBL1913212 | 0.87 | KMT2A (0.43) | TLR2TLR1BACE1KMT2AL3MBTL1 | |
| SCHEMBL14428332 | 0.86 | KMT2A (0.44) | TLR2TLR1BACE1KMT2AL3MBTL1 | |
| SCHEMBL8249851 | 0.84 | KMT2A (0.40) | TLR2TLR1BACE1KMT2AL3MBTL1 | |
| SCHEMBL19180879 | 0.84 | KMT2A (0.40) | TLR2TLR1BACE1KMT2AL3MBTL1 | |
| SCHEMBL4517265 | 0.83 | KMT2A (0.39) | TLR2TLR1KMT2ARENPOLB | |
| SCHEMBL4517260 | 0.83 | KMT2A (0.39) | TLR2TLR1KMT2ARENPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| EP-1907359-A2 | 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007006534-A2 | PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | TLR2 2086/4885TLR1 1343/4885BACE1 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.